{"id":"ac-4-t-4","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This appears to be a cell-based immunotherapy, likely involving autologous or allogeneic T cells engineered to recognize and attack malignant cells. The nomenclature suggests a multi-component cellular construct, possibly combining multiple targeting or functional domains to enhance anti-tumor activity and persistence.","oneSentence":"AC*4-T*4 is an engineered T cell therapy designed to target and eliminate cancer cells expressing specific tumor antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:09.839Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT00336063","phase":"PHASE1","title":"Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-03-03","conditions":"Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma","enrollment":18},{"nctId":"NCT04128501","phase":"PHASE2","title":"Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-05","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT02530463","phase":"PHASE2","title":"Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-08","conditions":"Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome","enrollment":99},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT04373031","phase":"PHASE2","title":"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2020-12-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":12},{"nctId":"NCT07197697","phase":"PHASE2","title":"A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-10-10","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT03283384","phase":"PHASE2","title":"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2019-06-15","conditions":"Breast Neoplasms","enrollment":100},{"nctId":"NCT02957968","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","status":"ACTIVE_NOT_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2017-01-24","conditions":"Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer","enrollment":46},{"nctId":"NCT02397720","phase":"PHASE2","title":"Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-04-07","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":150},{"nctId":"NCT03813147","phase":"PHASE1","title":"Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-17","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":12},{"nctId":"NCT01998035","phase":"PHASE1, PHASE2","title":"Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies","status":"TERMINATED","sponsor":"Columbia University","startDate":"2013-11","conditions":"Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma","enrollment":58},{"nctId":"NCT06404463","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-06","conditions":"Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer","enrollment":76},{"nctId":"NCT00003782","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"1999-03","conditions":"Breast Cancer","enrollment":5351},{"nctId":"NCT05048862","phase":"","title":"The Neuroimage Study of the Neuromuscular Disorders.","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-08-01","conditions":"Neuromuscular Diseases","enrollment":500},{"nctId":"NCT00499083","phase":"PHASE2","title":"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-05-01","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT05862610","phase":"PHASE2","title":"The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-30","conditions":"Breast Neoplasm","enrollment":150},{"nctId":"NCT05678933","phase":"PHASE3","title":"AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-01","conditions":"Peripheral T-cell Lymphoma Targeted Therapy","enrollment":200},{"nctId":"NCT04170465","phase":"PHASE2","title":"Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2019-10-29","conditions":"Breast Cancer Female","enrollment":70},{"nctId":"NCT01168219","phase":"PHASE2","title":"Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-15","conditions":"Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":68},{"nctId":"NCT01547741","phase":"PHASE3","title":"Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2012-04","conditions":"Breast Cancer","enrollment":1871},{"nctId":"NCT05302336","phase":"PHASE4","title":"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":402},{"nctId":"NCT04038489","phase":"PHASE2","title":"COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2019-10-18","conditions":"Breast Cancer, Estrogen Receptor-positive Breast Cancer","enrollment":""},{"nctId":"NCT05088057","phase":"PHASE2","title":"Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Aiping Shi","startDate":"2021-09-20","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT02018458","phase":"PHASE1, PHASE2","title":"Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2014-05","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT00004067","phase":"PHASE3","title":"Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2000-02","conditions":"Breast Cancer","enrollment":2130},{"nctId":"NCT00014222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-12-04","conditions":"Breast Cancer","enrollment":2104},{"nctId":"NCT00206518","phase":"PHASE2","title":"Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients","status":"COMPLETED","sponsor":"Mothaffar Rimawi","startDate":"2004-09","conditions":"Breast Cancer","enrollment":167},{"nctId":"NCT00129376","phase":"PHASE2","title":"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2003-02","conditions":"Breast Cancer","enrollment":63},{"nctId":"NCT00005639","phase":"PHASE1","title":"Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2000-03","conditions":"Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":34},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT02379585","phase":"PHASE1, PHASE2","title":"Fasting on Newly Diagnosed Breast Cancer","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2013-01","conditions":"HER2-positive Breast Cancer","enrollment":8},{"nctId":"NCT00093795","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-10","conditions":"Breast Cancer","enrollment":4894},{"nctId":"NCT02769104","phase":"PHASE3","title":"Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-05","conditions":"Neoadjuvant Therapy","enrollment":120},{"nctId":"NCT02953184","phase":"PHASE2","title":"Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Jilin University","startDate":"2016-11","conditions":"Antineoplastic Combined Chemotherapy Protocols","enrollment":160},{"nctId":"NCT03242551","phase":"PHASE2","title":"Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2017-11-08","conditions":"Breast Neoplasms","enrollment":120},{"nctId":"NCT00021255","phase":"PHASE3","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-04","conditions":"Breast Neoplasms","enrollment":3222},{"nctId":"NCT00066807","phase":"PHASE3","title":"Premenopausal Endocrine Responsive Chemotherapy Trial","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-08","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT02613026","phase":"PHASE3","title":"Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer","status":"COMPLETED","sponsor":"307 Hospital of PLA","startDate":"2009-07","conditions":"Breast Neoplasms","enrollment":104},{"nctId":"NCT00820690","phase":"","title":"Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Barretos Cancer Hospital","startDate":"2008-07","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT01339663","phase":"PHASE1","title":"Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-03","conditions":"Recurrent Melanoma, Stage IV Melanoma","enrollment":12},{"nctId":"NCT00312208","phase":"PHASE3","title":"Docetaxel in Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-11","conditions":"Breast Cancer","enrollment":3299},{"nctId":"NCT01129180","phase":"PHASE1","title":"Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma","status":"COMPLETED","sponsor":"Pierluigi Porcu","startDate":"2010-05","conditions":"Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":8},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT00016276","phase":"PHASE3","title":"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-05","conditions":"Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer","enrollment":396},{"nctId":"NCT00365365","phase":"PHASE2","title":"Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-08","conditions":"Breast Cancer","enrollment":214},{"nctId":"NCT00525642","phase":"PHASE2, PHASE3","title":"Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2003-06","conditions":"Breast Neoplasms, Adjuvant, Chemotherapy","enrollment":603}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CTX+Anthracyclines, Docetaxel"],"phase":"phase_3","status":"active","brandName":"AC*4-T*4","genericName":"AC*4-T*4","companyName":"Zhejiang Cancer Hospital","companyId":"zhejiang-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC*4-T*4 is a protein modality that has been studied in clinical trials for various breast cancer conditions, including breast adenocarcinoma, estrogen receptor-negative breast cancer, and estrogen receptor-positive breast cancer. It has been used in combination with chemotherapy agents such as doxorubicin, cyclophosphamide, and paclitaxel in trials like NCT02957968.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}